Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) and AleAnna (NASDAQ:ANNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Institutional and Insider Ownership
60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of AleAnna shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 42.9% of AleAnna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Lexeo Therapeutics has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, AleAnna has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexeo Therapeutics | N/A | N/A | -$99.96 million | ($2.19) | -3.05 |
| AleAnna | $25.04 million | 11.18 | $1.80 million | $0.04 | 105.00 |
AleAnna has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Lexeo Therapeutics and AleAnna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexeo Therapeutics | N/A | -67.33% | -55.98% |
| AleAnna | 7.19% | 3.31% | 1.93% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Lexeo Therapeutics and AleAnna, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexeo Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
Lexeo Therapeutics currently has a consensus price target of $18.88, suggesting a potential upside of 182.98%. Given Lexeo Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Lexeo Therapeutics is more favorable than AleAnna.
Summary
AleAnna beats Lexeo Therapeutics on 8 of the 14 factors compared between the two stocks.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
